(Q33420096)

26 July 2017

title

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study (English)

1 reference

26 July 2017

0 references

Claudia Pena Rossi

1

1 reference

26 July 2017

Stephen B Hanauer

2

1 reference

26 July 2017

Ratko Tomasevic

3

1 reference

26 July 2017

John O Hunter

4

1 reference

26 July 2017

Ira Shafran

5

1 reference

26 July 2017

Hans Graffner

6

1 reference

26 July 2017

publication date

20 March 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

9

1 reference

26 July 2017

page(s)

22

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

copyright license

start time

20 March 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Immune dysfunction in inflammatory bowel disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Advances in biologic therapy for ulcerative colitis and Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Conventional therapy for Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

European evidence based consensus on the diagnosis and management of Crohn's disease: special situations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Inflammatory bowel disease: etiology and pathogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-22

Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-22

Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-22

A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-22

An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-22

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674451

Treatment Of Crohn’s Disease With Interferon A Preliminary Clinical Trial

31 October 2018

1 reference

12 December 2020

[Alpha-interferon therapy in Crohn's disease: initial clinical results]

1 reference

12 December 2020

Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C

1 reference

12 December 2020

Inflammatory bowel disease: germs or genes?

1 reference

12 December 2020

Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice

1 reference

12 December 2020

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis

1 reference

12 December 2020

Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-230X-9-22

1 reference

26 July 2017

1 reference

26 July 2017

1 reference